RedHill Biopharma Announces New Opaganib Data For Nuclear Radiation Injury

RedHill Biopharma Ltd RDHL announced in vivo results from a new preclinical study evaluating the effects of opaganib] on radiation-induced hematologic and renal toxicity, undertaken by RedHill and its partner Apogee Biotechnology Corporation.
The results exhibit that opaganib exerts a protective impact on key hematological and kidney function parameters following total body irradiation (TBI).
Related: RedHill Says Opaganib Has Potential As Nuclear Radiation Protection For Homeland Security Countermeasures.
The data is consistent with recently published U.S. government-funded in vivo opaganib data and further supports opaganib's planned development under the Animal Rule for nuclear radiation protection.
Opaganib can be administered 24 hours or later after radiation exposure, is highly stable with a more than five-year shelf-life, easy to administer and distribute, and demonstrated its clinical safety profile in various human clinical studies and expanded access uses in other indications.
Price Action: RDHL shares are up 3.09% at $0.50 on the last check Thursday.